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INTRODUCTION
Physicians regularly prescribe drugs to children, by necessity, without the guidance of clinical trials that test
drugs to determine their safety and ecacy in this population. Often times, such therapies have harmful
eects, creating grave dangers and risks, including death, for some pediatric patients. Physicians' extensive
o-label use of drugs to treat children may lead one to conclude that children are already being used as
research subjects everyday. Yet, prior to the passage of the FDA's Final Rule mandating drug sponsors
to test drugs on children and the pediatric exclusivity provision of the Food and Drug Modernization Act,
there was little incentive for the pharmaceutical industry to include children in their clinical studies and,
thus, they did not. However, as a result of both initiatives, the number of children in clinical trials has
1risen. There is an estimated 45,000 children participating in industry-sponsored testing of new drugs, up
from about 16,000 in 1997.
This paper examines both the Food and Drug Administration's Final Rule, which mandates drug sponsors
to conduct pediatric research on their products prior to FDA approval and Section 111 of the Food and
Drug Modernization Act, which provides economic incentives for drug sponsors to include children in re-
search studies on their products. This paper concludes that Congress should renew the pediatric exclusivity
provision of the Food and Drug Modernization Act, but with modications as to provide incentives to drug
sponsors for testing products on children that are not as burdensome to the elderly and the poor. After
a historical review of the ills of pediatric testing, the paper discusses the need for more studies to be con-
ducted regarding the eects of drugs commonly prescribed in children. The paper then discusses the need
for regulation in clinical trials involving children. Next, the paper discusses past eorts of Congress and
the FDA to encourage drug sponsors to include the pediatric population in research trials before marketing
their products and then examines the latest eorts of both to encourage such studies. In the nal section,
the paper proposes modications to FDAMA Section 111 to ensure that the legislation is meeting its goal
of including children in more clinical trials in eorts to provide more labeling information in therapies used
on children.
I.
THE NEED FOR REGULATION IN PEDIATRIC RESEARCH
The history of experimental research on human beings is plagued with horric instances of abuse such as
World War II Nazi experiments on people that resulted in the Nuremberg trials1, the Tuskegee experiments
1Leonard H. Glantz, Conducting Research with Children: Legal and Ethical Issues, J. Amer. Acad. of Child
and Adol. Psych., 34: 1283-91, at 1285 (1996).
2in which African-American men were denied treatment for syphilis2, and the Willowbrook experiments in
which institutionalized children were intentionally infected with hepatitis and observed to determine the
eects of a vaccine for the disease.3 Recent examples, such as the death of a three-year-old in a cancer study
treatment4 and the death of a nine-month-old given an experimental drug for reux,5 serve as reminders
that using humans as research subjects continue to pose signicant risks. As such, modern scientists have
approached the continued use of humans as research subjects with caution, especially where children are
involved.
A. Historical Abuses of Children in Clinical Trials
Children were historically excluded from clinical studies, with the exception of vaccine development. There
was hesitation concern on the part of many over drug therapy in the pediatric population. Indeed, the
dogma of the day was simple: it was considered unethical to enroll children in experiments.6 Children were
a population to be protected from the unpredictability of therapeutic trials.7
Nonetheless, numerous clinical studies conducted in the development of vaccines continued to have large pe-
diatric populations.8 During the nineteenth century, the amount of pediatric research conducted increased
2See id. at 1285.
3Robert M. Nelson, Children as Research Subjects, in Beyond Consent: Seeking Justice in Research 47, 49
(Jeffrey P. Kahn, et al., eds., 1998). In this study, researchers exposed a group of mentally challenged
students to a strain of the hepatitis virus intentionally, so that they could ``understand the natural history
and prevention of this disease.'' This experiment is discussed in greater detail infra at Section II. A.
4Alice Dembner, Dangerous Dosage to Make Pediatric Medicine Safer, Boston Globe, February 18, 2001, at A1.
A 3-year-old diagnosed with a cancerous stomach mass and researchers in cancer study misdiagnosed the child's
condition and he later died. An investigation by the Boston Globe revealed, ``Medical experiments across the
country appear to have killed at lease eight children and subjected hundreds more to harmful side effects in
the last seven years.'' Id. at A1.
5Drug Study Blamed in Baby's Death: 9-Month Old was Part of Heartburn Medical Trial, Milwaukee Journal
Sentinel, April 28, 2000, at A9.
6Jane E. Henney, Remarks at the Institute of Medicine National Academy of Sciences Roundtable on Research
and Development of Drugs, Biologics, and Medical Devices, entitled, ``Rational Therapeutics for Infants and
Children'' (May 24, 1999). (transcript available at http://www.verity.fda.gov/search97cgi/) (visited May 1,
2001).
7See id.
8Leonard H. Glantz, Research with Children, 24 J.L. & Med. 213, 215 (1994) (stating that ``children have
been particularly subjected to abuses by researchers and `those who do research with children today have
3substantially in an earnest eort to improve children's health through advanced vaccinations and inocula-
tions.9 Although the researchers conducting these trials made signicant oncological contributions by curing
serious childhood diseases, they often placed pediatric research subjects at considerable risk.10
High-risk experiments involving medical research on children continued throughout the late nineteenth cen-
tury. Researchers primarily focused their experiments upon institutionalized children in asylums and orphan-
ages11 as control groups for research on measles and other diseases12, theories, and medical treatments.13
The inherent dangers in these trials were manifested through many cases.14 For instance, in a North Carolina
orphanage in 1912, children were administered an experimental tuberculosis vaccine15 and were later found
to have a greater tendency to contract the disease than the children who had not received the experimental
treatment.16
Newer, more sophisticated drugs and medical tools, such as the x-ray, prompted continued medical research
on children in the twentieth century, with a particular interest in metabolism and digestion.17 Many of these
experiments required pediatric subjects to undergo medically unnecessary procedures and discomfort.18 The
inherited the legacy of researchers who have come before them.'''). Accredit all paragraphs regarding the
history of experimentation on children to his book.
9Susan E. Lederer & Michael A. Grodin, Historical Overview: Pediatric Experimentation, in
Children as Research Subjects, 3, 19 (Michael A. Grodin & Leonard H. Glantz, eds.,1994) (stating that the
history of pediatric research is filled with stories of abuses).
10See id. at 4-8 (describing pediatric trials that led to smallpox vaccinations and how pediatric research
led to anti-toxins for diphtheria, which was main cause of death in 19th century children.)
11Weisstub, et al., Biomedical Experimentation with Children: Balancing the Need for Protective Measures with the Need to Respect Children's Developing Ability to Make Significant Life Decisions for Themselves,
in Research on Human Subjects 380, 381 (David N. Wesstub, ed., 1998) (quoting a New York pediatrician who
said that asylum children were ideal subjects for research because of the researcher's ability to control
subjects.)
12See id. at 380-81 (noting that trials were conducted for measles similar to those of smallpox trials).
13Glantz, supra note 8, at 216 (describing experiments with x-rays and other experiments where doctors
performed spinal taps on children to determine if they are harmful.)
14See Lederer & Grodin, supra 9, at 7 (explaining that medical interest in diseases like cancer, leprosy,
syphilis, gonorrhea, tuberculosis and yellow fever prompted researchers to infect children and other research
subjects deliberately).
15See id. at 8 (describing 1912 tuberculosis study where 262 children at a North Carolina orphanage were
injected with an experimental tuberculosis vaccine).
16See id. at 8 (noting that when North Carolina Public Health Services tested subjects in 1914, ``guinea pigs
who had received the vaccine yielded more quickly to tubercular infection than those not vaccinated'').
17See id. at 9 (explaining doctors' use of x-rays to study normal development of children, and the great
interest in studying human digestion using stomach tubes in children and infants).
18See id. at 10 (describing gastrointestinal studies that caused subjects to become extremely ill and other
tests where children had to be sedated and restrained to comply with protocol requirements.)
4negative publicity surrounding these trials, however, led to increased scrutiny of these abusive experiments
by members of the medical community and society-at-large.19
Pediatric subjects continued to endure mistreatment well into the second half of the twentieth century de-
spite this increased scrutiny. 20 The hepatitis testing conducted at the Willowbrook State School beginning
in 1955 and continuing through the early 1970s is one of the most infamous examples of pediatric clinical
testing abuse.21 Although researchers conducting this clinical trial obtained parental permission, the parents
were not fully apprised of the risks involved in the experiment.22 The head of the research team defended the
Willowbrook experiment, explaining that research subjects were not placed at an increased risk of serious
illness than the school's other students. In fact, he predicted that research subjects were at a lower risk
of serious illness than the school's other students due to the poor conditions that existed at the school. 23
Despite the head researcher's defenses of the study, critics continued to question its merits24 While this
study and others similar to it shed light on the ills of pediatric research, abuses continue in this country and
throughout the world even today.
In the early 1990s in New York City, thirty-six healthy children between the ages of six and ten years old
19See Glantz, supra note 8, at 216 (describing 1941 incident where editor of Journal of Experimental Medicine
refused to publish study in which 12 healthy infants were inoculated with herpes, even though these children
were volunteered by parents for study).
20See Lederer & Grodin, supra note 9, at 11-13 (explaining that groups opposing animal research began to
oppose pediatric research subject abuse in late 19th century, and were later joined by members of medical
community and journalists).
21A.E. Ryan, Protecting the Rights of Pediatric Research Subjects in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use,
23 Fordham International Law Journal. 848 (2000) (quoting Robert M. Nelson, Children as Research Subjects, in
Beyond Consent: Seeking Justice in Research 47, 49 (Jeffrey P. Kahn, et al., eds., 1998). In this study,
discussed briefly supra, a group of mentally challenged students were exposed to a strain of the hepatitis
virus intentionally, so that researchers could ``understand the natural history and prevention of this
disease.''
22See id. at 51. (noting `` ` consent forms that parents signed to allow their children to be infected with
the virus' read as though their children were to receive a safe vaccine'').
23See id. at 50 (citing interviews with the head of Willowbrook research team, Saul Krugman, in which
he states that because subjects were protected from common diseases at Willowbrook, participation in the
hepatitis study was more safe than the school's ordinary living conditions, thus, an ethical study.)
24See id. at 50 (explaining that critics of the study questioned whether parents were forced into
consenting by promises of better conditions for the children, why similar tests were not conducted on adult
staff members of the facility, and why other prevention measures were not taken to control the spread of
disease.)
5participated in a research study where they were given doses of the diet drug fenouramine. Prior to this
study, the FDA had removed this drug from the market for causing death in adult patients, however, ex-
posure to fenouramine was found by researchers to measure a hormone in the subjects' brains that was
supposedly linked to antisocial behavior. In the course of this three-year study, researchers forced children to
fast for eighteen-hour periods and then drew multiple blood samples from catheters inserted in their veins.
The result of this process left some of the children feeling nauseous and complaining of headaches.
While these horric examples illustrate the extreme need for regulation in the area of medical testing of
human beings, especially children25, the importance of safe clinical studies cannot be overstated. Regulation
in this area helps to achieve the necessary balance between conducting safe research trials and the need for
the valuable information about the eects of drugs in children which is derived from such experiments.
B. Pharmaceutical Companies' Exclusion of Children from Clinical Studies
Many pharmaceutical companies resist conducting research on children26 because of the ethical and legal
concerns involved in conducting pediatric trials, and the diculty recruiting subjects27 for testing. A study
on the eects of the drug Enbrel on children with rheumatoid arthritis demonstrates the diculties phar-
maceutical companies face when conducting pediatric research.28 First, the market for pediatric medicines
is small. Of the estimated two million Americans with rheumatoid arthritis, less than 100,000 are children,
and only half of those children would be eligible.29 Thus, drug companies can expect little in return for
25Presently, there is an estimated 45,000 children participating in industry-sponsored testing of new
drugs, up from about 16,000 in 1997. These numbers are expected to continue to rise with the promulgation
of initiatives to encourage safe pediatric testing. See Dembner, supra note 4, at A1, quoting Christopher-Paul
Milne, a senior research fellow at the Tufts University Center for the Study of Drug Development.
26Ryan, supra note 21.
27Ralph E. Kauffman, Scientific Issues in Biomedical Research with Children, in Children as Research Subjects,
30, 38 (Michael A. Grodin and Leonard H. Glantz, eds. 1994) (stating that many protocols are impeded because
researchers are not able to enroll sufficient number of subjects that conform to study's criteria.)
28Dembner, supra note 4.
29See id.
6conducting such costly studies30 on children without some external nancial incentive. In the case of the
Enbrel study, researchers tested adults and children simultaneously to get the drug approved as an \orphan
drug," a lucrative designation given to treatments for rare diseases.31 Orphan drug status entitles a drug
company to tax credits and seven years of \market exclusivity," whereby generic companies are precluded
from competing with the name brand drug until the exclusive license expires.32
Not only is the demand of drugs for pediatric patients relatively small, few therapeutic indications are unique
to the pediatric patient population.33 Furthermore, from an actuarial perspective, humans spend about 60
to 80 years as adults, whereas they spend only approximately 16 years as children.34 Finally, since o-label
prescribing is considered perfectly acceptable medical practice, physicians are still able to administer drugs
to children without costly clinical trials.35 As a result, there are few incentives for pharmaceutical companies
to develop drugs and drug dosing guidelines for infants and children. Thus, a large number of medications
commonly prescribed for children are not tested on pediatric subjects, creating a grave dangers and risks for
young patients.36
II.
THE NEED FOR INFORMATION ABOUT THE EFFECTS OF DRUG
THERAPIES IN CHILDREN
30R. Coopman, The Pros and Cons of the Policy on Pediatric Trials, Chain Drug Review, 23: RX 8 (2000)
(stating that the average testing and approval process for a drug is estimated to cost anywhere from $200,000
to $3 million).
31Dembner, supra note 4.
32Orphan Act, Pub. L. No. 97-414, 96 Stat. 2049 (codified as amended at 21 U.S.C. x 360aa-360ee
(1994); 26 U.S.C. x 45C (1994); 42 U.S.C. x 236 (1994)).
33Jeffrey L. Blumer, Off-Label Uses of Drugs in Children, American Academy of Pediatrics, 104: 598-602, 598
(1999).
34Id. at 598.
35Veronica Henry, Off-Label Prescribing: Legal Implications, J. Legal Med. 20:3 (September, 1999) at 1
(stating that the American Medical Association estimates 40%-60% of all prescriptions in the United States are
written for drugs being used for something other than their approved purpose.)
36See National Institutes of Health (``NIH''), NIH Policy and Guidelines on the Inclusion of Children as
Participants in Research Involving Human Subjects, March 6, 1998 (stating that AAP has reported that ``only a
small fraction of all drugs and biological products marketed in the U.S. have had clinical trials for use in
pediatric patients'').
7A.
Physiological Dierences Between Adults and Children
Because children are subject to many of the same diseases as adults, physicians often treat children, by
necessity, with the same drugs and biological products used by adults, even if these products have not been
tested on children.37 Physicians' extensive o-label38 use of drugs to treat children has leads one to the
conclusion that children are already being used as research subjects everyday. Because physicians prescribe
drugs to children without the controlled supervision of a clinical trial, such prescriptions often result in
disastrous consequences for the children and their families.39
The physiological dierences between children and adults require scientists to conduct pediatric research.40
The most distinguishing feature dierentiating children from adults are the signicant physical and mat-
uration changes that occur.41 The course of an individual's development with regard to drug absorption,
metabolism, and excretion substantially restricts the extrapolation of data from adults to children.42 One
horric example of children metabolizing drugs dierently than adults was the wide-spread use of the an-
tibiotic chloramphenical in premature infants to treat infections. A study in 1959 revealed that babies were
unable to metabolize the drug properly. Chloramphenical, which had only been approved for use in adults
for infections resistant to penicillin, resulted in \gray baby syndrome" and death for some infants who accu-
mulated toxic levels of the drug in their system.43 Furthermore, not only is a child's physiology signicantly
37J. Rosato, The Ethics of Clinical Trials: A Child's View, 28 J.L. Med. & Ethics 362 (2000) at note 28.
38Blumer, supra note 33 at 599. Off-label means that while the FDA has approved the drug for adults, it has
not approved or labeled it for children.
39Id. at 598.
40Jeffrey L. Blumer, Is Pediatric Labeling Really Necessary?, American Academy of Pediatrics, 104: [suppl]
593-597, 596.
41Id. at 596.
42Id. at 597.
43See J.S. Abramson and M.E. Holland, Off Label Use of Antimicrobial Agents in Infants, Children and Adolescents: A time for Action,
8dierent from that of an adult, but a child's physiology is dierent from that of another child in a dierent
age group.44
As a result, the dierences between adults and children, and even the dierences among children themselves,
signicantly impact whether and how a drug can be used on a pediatric patient.45 Drug studies conducted
on adults or on children of only one age group may not adequately predict whether a drug will be toxic if
prescribed to a child of another age group.46 Thus, pharmaceutical companies' failure to test medicines in
children of all age groups may result in serious illness or even death.
B. O-Label Prescriptions
Without adequate pediatric testing, physicians confront a serious ethical dilemma: prescribe medication or
perform a procedure that potentially benet the child, or refrain from this treatment due to inadequate in-
formation about its eects on children.47 By prescribing the drug or performing the procedure, the physician
may run the risk of creating an unexpected adverse eect on the child that could subject the physician to
liability.48 Conversely, by failing to prescribe the drug o-label, the doctor may be preventing the child from
receiving the most eective intervention available.49
The FDA has implemented some initiatives to improve both the quality and quantity of pediatric prescribing
Ped. Infec. Dis. J. 17: 739-44, at 742 (1998).
44See generally Blumer supra note 40.
45Kauffman, supra note 27 at 39 (stating that ``capacity to metabolize and excrete drugs changes throughout
infancy, childhood and adolescence).
46Blumer, supra note 40 at 595 (explaining that adult tests may not accurately predict the minimal effective
dose, maximum titrated dose, therapeutic effect or adverse reactions in the child).
47See American Academy of Pediatrics, Committee on Drugs, Guidelines for the Ethical Conduct of Studies to
Evaluate Drugs in Pediatric Populations, Pediatrics, Feb. 1995, 286, 286 (explaining that using non-validated
drugs, which fails to create data for future use, may create greater risk than administering drugs in
controlled clinical trial.)
48S. Stolberg, Once Excluded, Children Now Take Part in Drug Tests, Milwaukee Journal Sentinel (February 11,
2001) at 17A (quoting doctor who cautiously bases chemotherapy doses on height and weight, ``I might be able
to treat their cancer more aggressively, but I don't know how to safely do that.''
49See id. at 17A. See generally Rosato, supra note 37v.
9guidelines available to health care professionals. First, the Pediatric Studies Page for a New Drug Applica-
tion was modied.50 Prior to the modication, the manufacturer had to justify the necessity of conducting
a pediatric study. Under the modication, the manufacturer must justify why a pediatric study is not going
to be conducted.51
Secondly, standards were developed for clinicians to follow for the extrapolation of data from adult clinical
trials, when appropriate, or for the use of selective pediatric data (pharmacokinetics) in formulating pedi-
atric use guidelines to help physicians prescribe drugs o-label more safely.52 For example, one method to
make the adjustment from an adult dosage to a child dosage is an extrapolation based on weight.53 The
arbitrariness of this method, and its failure to take into account any specic dierences in drug absorption
between children and adults makes this an inadequate method for determining proper dosages for children
without placing them at a substantial risk for injury or even death.54 Moreover, adjusting doses solely based
on weight often underdose infants and children, while overdosing neonates.55
Another suggested method for determining dosages of medication for children is to extrapolate dosage infor-
mation from available medical literature.56 In this instance, the clinician's decision for treatment is based
on studies published in medical journals. Yet, this method is equally inadequate. Research shows that the
reporting of clinical research in medical literature is burdened with paucities, including ill-prepared study
designs, inaccurate documentation, questionable data collection methods, awed statistical analyses, and in-
defensible conclusions.57 Moreover, unlike the FDA's review of data from a clinical trial, journal editors and
50See Taylor & Francis, Off Label Prescribing, J. Legal Med. 20:3 (September, 1999).
51Id.
52See Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of
``Pediatric Use'' Subsection in the Labeling, 59 Fed. Reg. 64, 240 (1994) (amendment responding to the
inadequacy of drug labels in supplying information for use in pediatric populations.) This amendment is
discussed, infra, in Section IV.
53Blumer supra note 33 at 600.
54Id. at 600.
55Id.
56Henry supra note 35 at FN 110.
57S.J. Pocock, M.D. Hughes, et al., Statistical Problems in the Reporting of Clinical Trials: A Survey of Three Medical Journals,
N. Engl. J. Med. 317: 426-32, (1987) cited in Blumer supra note 40.
10reviewers usually do not have access to all the data when reviewing the results of a clinical trial.58 Therefore,
drug therapy decisions that rely solely upon medical literature may also lead to ineective therapy or toxic
results.
Unfortunately, this practice of o-label prescribing using weight charts and medical literature by physicians
often constitutes the standard of care for many children.59 Startling statistics show that only one-fth of
all drugs on the market have been labeled for use by infants and children.60 Moreover, 60 to 70 percent of
drugs have no indication for their use in children under age 12, and 95 percent of drugs used in neonatology
are administered o-label.61 As a result, children remain \therapeutic orphans," a term coined to describe
children who are experimented on outside formal clinical trials.62 The problem of therapeutic orphaning
hinders the development and application of potentially life-saving therapies for pediatric patients, sometimes
causing children to suer grave and dangerous harm. More than 70% of all Physicians' Desk Reference
(PDR) entries have either no existing dosing information for pediatric patients or explicit statements that
the safety and ecacy in children have not been determined.63 This quandary is particularly evident in
medications used to treat serious illnesses, such as cancer and AIDS.64 Additionally, certain age groups are
commonly excluded from drug trials, resulting in incomplete and unreliable outcomes concerning the safety
58Id.
59Only one-fifth of all drugs on the market have been labeled for use by infants and children. 62 Fed.
Reg. 43,899-916, at 43,902, col. 1 (1997). Moreover, 60 to 70 percent of drugs have no indication for their
use in children under age 12, and 95 percent of drugs used in neonatology are administered off-label. V.
DeBenedette, Suffer the Children, Drug Topics, 142: 2 (January, 1998). See also Blumer supra note 33 at 599
(stating, ``The prescribing of drugs for off-label use is entirely proper'').
6062 Fed. Reg. 43,899-916, at 43,902, col. 1 (1997).
61DeBenedette supra note 59 at 2.
62See Ryan supra note at 856.
63Id.
64Ryan supra note 21 at 857. (noting that less than half of FDA approved drugs used to treat human
immunodeficiency virus (``HIV'') and opportunistic infections caused by HIV are labeled for use in children.)
According to the AAP, 81% of the drugs listed in the 1991 Physician's Desk Reference disclaimed all use in
children, or at least disclaimed use in children of certain age groups. Id. In 1992, 79% of the 19 new
molecular entities that were approved by the FDA were not labeled for use in pediatric patients. Committee
on Drugs, supra note 47 at 286. In 1996, only 37% of new molecular entities with potential usefulness in
children had some pediatric labeling. NIH, supra note 36 at 43902.
11and eectiveness of drugs for these patients.65 Therefore, despite the controversies surrounding medical
studies that are conducted on children the scientic need for such experimentation is apparent.66
IV.
CONGRESS' AND FDA'S PAST ATTEMPTS TO IMPROVE DRUG
LABELING FOR CHILDREN67
Prior to initiatives to encourage drug sponsors to include the pediatric population in clinical studies on
drug therapies, children were likely to remain therapeutic orphans. During the past two decades, however,
the medical community has expressed increased concern that the majority of drugs widely used on children
lack testing regarding the safety and eectiveness of such usage. In response to this concern, Congress
and the Food and Drug Administration have undertaken numerous initiatives to address the problem of
inadequate pediatric testing and unsubstantial pediatric use information available in drug and biological
product labeling.
The rst earnest eorts to improve pediatric labeling of drugs began in 1974.68 At that time, the FDA and
the American Academy of Pediatrics (AAP) agreed to develop and implement a solution for the lack of drugs
in the market labeled for pediatric use.69 The AAP's Committee on Drugs then issued general guidelines
outlining procedures for the evaluation of drugs to be used in pediatric patients. Subsequently, the FDA
65See NIH, supra note 36 (explaining that there is almost no information for most classes of drugs for use in
children under age two).
66See Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological
Products in Pediatric Patients, 62 Fed. Reg. 43900, 43901 (1997) (stating that pediatric testing is
necessary to determine appropriate drug dosing guidelines, as incorrect dosing can lead to ``unexpected
adverse reactions,'' and ineffective treatment).
68General Guidelines for the Evaluation of Drugs to be Approved for Use During Pregnancy and for Treatment of Infants and Children,
Committee on Drugs, American Academy of Pediatrics (Evanston, Ill., 1974), cited in K.R. Karst,
Pediatric Testing of Prescription Drugs: The Food and Drug Administration's Carrot and Stick for the Pharmaceutical Industry,
49 Am. U.L. Rev. 739 (2000) at FN 37.
69See id.
12adopted AAP's guidelines and incorporated them into clinical guidelines in 1977.70 A couple of years later,
in 1979, the FDA announced a \Pediatric Use" regulation. This regulation stipulated requirements to
which drug sponsors had to comply in order to include pediatric uses on product labels.71 The regulation's
requirements included a mandate that drug sponsors include information collected from clinical studies
performed during a product's safety and eectiveness evaluation on the product's labeling.72 The 1979
regulation was amended in 1994,73 thereby requiring drug sponsors to modify drug labels. Modication of a
drug label was to be done based on an assessment of current pediatric data to seek either a labeling change
for pediatric use or to include a statement, such as: \Safety and eectiveness in pediatric patients have not
been established."74 The amended regulation essentially gave the pharmaceutical industry the option as to
whether it would conduct pediatric research and include the data on labels, or include a statement on the
product indicating that such studies had not been conducted.
By failing to mandate the pharmaceutical industry to include pediatric data on labels in both the 1979
\Pediatric Use" regulations and in the amended 1994 rule, the FDA essentially removed any incentive for
70See U.S. Department of HEW, PHS, FDA, Pub. No. 77-3041, General Considerations for the Clinical
Evaluation of Drugs in Infants and Children (1977) (outlining the guidelines for the evaluation of drugs in
pregnant women, infants and children.) cited in K.R. Karst, supra at 68.
71Labeling and Prescription Drug Advertising; Content and Format for Labeling for Human Prescription Drugs,
44 Fed. Reg. 37, 434 (1979) (codified at 21 C.F.R. pts. 201 and 202) (saying that the final rule's purpose
was to establish labeling standards for all prescription drugs.)
72See id. at 37, 459.
73Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of
``Pediatric Use'' Subsection in the Labeling, 59 Fed. Reg. 64,240 (1994) (amendment responding to the
inadequacy of drug labels in supplying information for use in pediatric populations.) (codified at 21 C.F.R.
201.57(f)(9)(vi) (1994)).
74See id. at 64, 241. This regulation required the label to include ``any limitations on the pediatric
indication, need for specific monitoring, specific hazards of the drugs, differences between pediatric and
adult responses to the drug, and other information related to the safe and effective use of the drug in
pediatric patients.'' Id. If substantial evidence failed to support a specific pediatric indication or a
pediatric use statement for a particular subgroup, the regulation required the labeling to include a statement
characterizing the limitation, such as ``safety and effectiveness in pediatric patients [below the age of ]
have not been established.
13drug sponsors to conduct clinical studies.75 While the purpose of the 1994 amendment to the regulation was
to counteract such a result,76 it neglected to provide an incentive to generate the inclusion of substantive
pediatric information on product labels.77 When the FDA compared the number of new molecular entities
approved in 1991 with those of 1996 with the potential usefulness in pediatric patients, fty-six percent
of the products approved in 1991 had some pediatric labeling at the time of approval.78 Yet, by 1996,
this number had plummeted and only thirty-seven percent of the products approved had some pediatric
labeling.79 Further, of the seven new molecular entities approved in 1991 for which post-approval pediatric
studies were promised, only one attained pediatric labeling by 1997.80 Evidently, the pharmaceutical industry
chose not to study its products for use in pediatric patients. While there was not an incentive to conduct
such research, neither was there a disincentive for choosing not to conduct such a study.81
Both the Clinton Administration, through the FDA, and Congress took action to remedy this problem of
excluding children from drug therapy trials.82 The FDA made clinical testing as well as the subsequent
75Dianne Murphy, Statement at the Anti-Infective Drugs Advisory Comm. Meeting of the Pediatric Subcomm.
(1999) (discussing the FDA's efforts in the 1970s and the agency's 1994 effort to include pediatric
information on drug labels did not result in sufficient pediatric information because the Industry was given
an option as to whether it will conduct the studies.)
76See Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of
``Pediatric Use'' Subsection in the Labeling, 59 Fed. Reg. at 64, 241 (``The final rule revises the current
``Pediatric Use'' subsection of the professional labeling requirements for prescription drugs to provide for
the inclusion of more complete information about the use of a drug in the pediatric population...'')
77Althea Gregory, Denying Protection to Those Most in Need: The FDA's Unconstitutional Treatment of Children
, 8 Alb. L.J. Sci. & Tech. 121, 131 (1997) (arguing that the ``Pediatric Use'' regulations did not result
in any changes to pediatric testing as evidenced by the fact that at least 71% of drugs still lack adequate
pediatric dosing information).
78Henney supra note 6.
79See id.
80See Id.
81See Off-Label Drug Use and FDA Review of Supplemental Drug Use and FDA Review of Supplemental Drug
Applications: Hearings Before the Subcomm. on Human Resources and Intergovernmental Relations of the House
Comm. On Gov't Reform and Oversight, 104th Cong. 109 (1996) (statement of Ralph Kauffman, M.D., Professor of
Pediatrics and Pharmacology at the University of Missouri, Kansas City and Director of Medical Research at the
Children's Mercy Hospital in Kansas City, on behalf of the AAP) (stating that only approximately 20% of all
drugs marketed in the United States have been labeled for use by infants and children and that since 1962, 80%
or more of approved drugs have been labeled for adult use with a disclaimer that they are not approved for use
by children) cited in K.R. Karst, supra note 68.
82See FDA Acts to Make Drugs Safer for Children (released November 27, 1998) http://www.fda.gov/bbs/topics/NEWS/NEW00666.html
(announcing the Administration's final rule to mandate pediatric studies.)
14labeling of drugs mandatory for pediatric patients under the Pediatric Final Rule.83 Conversely, instead of
setting forth a mandate to conduct studies, Congress created incentives for drug sponsors to conduct such
pediatric trials84, resulting in FDAMA Section III.
V.
FDA FINAL RULE ON PEDIATRIC LABELING
Past attempts to protect pediatric health and provide safe and eective products for children
are the hallmarks of change and innovation to the Food Drug and Cosmetics Act (\FDCA").
Strides in clinical pharmacology have identied how an array of factors aects the safety
and ecacy of drugs in various host patients. Both the FDA's Rule on Pediatric Labeling
(\Final Rule")85 and Section 111 of the Food and Modernization Act (\Modernization Act"
or \pediatric exclusivity provision")86 represent a culmination of the most recent eorts to
include children in clinical drug trials and, thus, adopt the \therapeutic orphan."
FDA regulations, with regard to the specic content and format of prescription drug labeling, stipulate
that pediatric labeling must be based on adequate, well-controlled studies involving children.87 Because
the FDA's customary rule has required labeling that species that such studies have not been conducted
in children88, many heavily used drugs in pediatric populations gained recognition of their utility and risks
83See infra discussion on the development and implications of the Final Rule.
84See infra discussion the development of the Food, Drug and Modernization Act, Section 111.
85See Final Rule: Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs
and Biological Productsin Pediatric Patients, 63 Fed. Reg. 66, 632 (1998).
86See FDCA 505A; 21 U.S.C. 355a (providing market exclusivity for sponsors who conduct pediatric studies of
drugs).
87Policy Statement -- Unapproved Uses of Approved Drugs: The Physician, the Package Insert, and the Food
and Drug Administration: Subject Review, 98 PED. 143 (July 1996).
88See Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of
``Pediatric Use'' Subsection in the Labeling, 59 Fed. Reg. at 64, 241.
15through clinical trial and error. Perhaps the failure of the 1994 voluntary labeling rule to increase the number
of products on the market with pediatric labeling contributed to the FDA's proposal of a regulation requiring
drug sponsors to conduct pediatric studies and to include the results of those studies on product labels in
eorts to guarantee the safety and eectiveness of drugs for pediatric patients.89 The FDA introduced the
proposed rule on August 15, 1997. The promulgation of the Final Rule occurred on December 2, 1998 and
took eect on April 1, 1999.
Although the drug manufacturers thought that the pediatric exclusivity provision of FDAMA, discussed
infra, would provide enough incentive to develop drugs for children, the FDA did not agree. Apparently,
the FDA thought that the provisions of the Modernization Act, which is presently scheduled to sunset in
2002, would be well complemented by a set of regulations requiring that all new drugs potentially helpful to
children be tested in the pediatric population, with penalties for drug manufacturers who fail to comply.90
The ultimate goal of the Final Rule is to have more drugs labeled for children, which is not a requirement
for the benets oered in the Modernization Act.91
The Final Rule distinguishes new drugs from currently marketed drugs. Under the Final Rule, the FDA
presumes that sponsors will study all new drugs in pediatric patients unless a waiver of this requirement
is justied.92 The FDA concluded that sponsors with currently-marketed products must conduct pediatric
studies if: (1) the use of the product among pediatric patients is great and the absence of labeling would pose
signicant risks to those patients, and (2) the product's claimed indications would \represent a meaningful
8963 Fed. Reg. at 66, 633.
90See generally 63 Fed. Reg. 66, 632.
91See id.
92The FDA may grant a waiver if the waiver request demonstrates that the product meets both of the following
conditions: (1) The product does not represent a meaningful therapeutic benefit for pediatric patients
over existing treatments, and (2) the product is not likely to be used in a substantial number of pediatric
patients. 63 Fed. Reg. at 66, 635, col. 2.
16therapeutic benet over existing treatments if studied in pediatric patients." If the FDA determines that
either a new or currently marketed drug provides a \meaningful therapeutic benet"93 for pediatric patients,
then the sponsor must develop and test a pediatric formulation. Drug sponsors can waive this requirement
when reasonable attempts to develop a pediatric formulation have failed.94
The regulation's nal notice provides that where children are not tested without securing the appropriate
waivers, penalties must be imposed,95 the eectiveness of the regulation's penalties for non-compliance is
questionable. According to the FDA's commentary, penalties include issuing injunctions, making ndings
of contempt, issuing nes, and requiring the manufacturer to assess the product's safety and eectiveness.96
Nevertheless, even if the regulation is violated, the drug will not be kept o or taken o the market \except
possibly in rare circumstances" that are not designated.97 Without the availability of these remedies, it is
not clear whether manufacturers would choose to withstand the imposition of existing penalties rather than
develop drugs for children. In addition to the other requirements of the rule, the regulations also provide
that children should be tested before the new drug is approved for adults, unless a deferral is warranted.98
It must be noted that the FDA's legal authority to mandate pediatric studies has been questioned on
grounds that the Final Rule expands the FDA's regulatory authority beyond the powers granted to it
by Congress. 99 The FDA relies on section 701(a) of the FDCA, which authorizes the FDA to issue
93The term ``meaningful benefit therapeutic benefit'' is defined as a significant improvement in the
treatment, diagnosis, or prevention of a disease, compared to marketed products adequately labeled for that
use in the relevant pediatric population.'' See 63Fed. Reg. at 66, 636.
94See generally 63 Fed. Reg. 66,632.
95See id.
9663 Fed. Reg. at 66, 636, col. 2.
97See id. at 66, 636, col.2.
98See id.
99Congress granted the FDA authority to set forth regulations to aid in the efficient enforcement
of the FDCA. See FDCA 701(a), 21 U.S.C. 371(a) (1994 & Supp. 1997). The limits to this authority
are, as with any agency, that the actions must reasonably relate to the agency's purposes. See
United States v. Nova Scotia Food Prod. Corp., 568 F.2d 240, 246 (2d Cir. 1977) (holding that a regulation
17regulations for the \ecient enforcement of the [FDCA]," to buttress its argument for mandated pediatric
studies.100 However, drug manufacturers have argued that even the most expansive interpretation of the
FDA's cited statutory authority to mandate pediatric studies cannot encompass the FDA's propositions for
new or currently marketed drugs.101 If this authority is left unchallenged, it is anticipated that the FDA
will expand its authority further if the Modernization Act expires on January, 2002 without renewal of the
pediatric exclusivity provision.102
VI.
FDAMA SECTION 111: THE 1997 PEDIATRIC EXCLUSIVITY PRO-
VISION
issued under section 701(a) of the FDCA will be sustained as long as it is reasonably related to the purposes
of the FDCA), cited in K. Karst, supra note 68.
100See Final Rule, supra note 85 at 66, 657 (noting that section 701(a) grants the FDA authority to mandate
pediatric studies for drug manufacturers).
101See generally letter from Bonnie J. Goldmann, M.D., Vice President Regulatory Affairs, Merck & Co., Inc.,
to FDA Dockets Management Branch, Docket No. 97N-0165 at 3 (Nov. 12, 1997) (arguing that the FDCA does not
authorize the FDA to require pediatric studies for new or currently-marketed drugs),cited in K.R. Karst supra
note 68.
102See id.
18In November 1997, Congress passed a sweeping reform of Food, Drug and Cos-
metics Act with its enactment of the Federal Food and Drug Administration
Modernization Act (FDAMA). This Act is considered to be the rst compre-
hensive drug reform legislation in 35 years103. Unlike past legislation aimed at
the FDA, the FDAMA aects the majority of products under the agency's reg-
ulation: foods, drugs, and medical devices. At the time it was passed in 1997,
the FDA predicted that the enforcement of this new legislation would be \one
of the most demanding challenges faced by the agency in its 92-year history."104
Two provisions of the FDAMA aim for performance of more clinical trials that are inclusive of likely pa-
tients. The rst provision pertains to the inclusion of women and minorities in clinical studies. Taking a
cautious approach, the FDAMA only directs the FDA to consult with the National Institutes of Health and
pharmaceutical industry representatives to administer guidance on the inclusion of women and minorities in
clinical trials.105 Beyond this, the law fails to impose any further obligations on the FDA or drug sponsors
to insure the inclusion of women and minorities in clinical studies.106
In the second provision, the FDAMA encompasses a more proactive approach to ensuring that the pediatric
population is included in clinical trials. Prior to the passing of the FDAMA, the FDA rarely mandated that
a drug be studied in children. In fact, as discussed supra, the vast majority of drugs approved under FDCA
amendments do not have approved indications for children. Ironically, both the 1938 and 1962 amendments
to the FDCA, however, were the result of therapeutic catastrophes in the use of untested drugs on children.
The rst amendments to the statute were made after the death of 107 children from sulfanilamide elixir
103The last major reform to the FDCA was the 1962 Kefauver-Harris Amendments. See Kauman, Status of Drug Approval
Processes and Regulation of Medications for Children, 7 CURR. OP. PEDS. 195 (1995).
104The FDA made this statement in a message to FDA Stakeholders. See Richard A. Merrill, Modernizing the FDA: An
Incremental Revolution, Health Aairs, (March, 1999 { April, 1999).
105See generally FDCA, Sec. 505(b)(1).
106See id.
19that used diethylene glycol as a solvent.107 Prior to marketing of the elixir, no toxicity testing had been
done. Similarly, another pediatric tragedy led to the passing of the 1962 amendments. The thalidomide
tragedy, where children whose mothers took thalidomide during pregnancy to prevent morning sickness and
their children were born with phcomelia and other debilitating birth defects,108 led to the requirement that
not only did drugs have to be safe, but they also had to be eective in the population in which they are to
be marketed.109 As a result of these amendments to the FDCA, the safety and ecacy in one population
could not be transferred to another population, such as the adult population to the pediatric population.
While these changes to the FDCA were signicant, the problem of medication use in children without proper
testing has not been solved. In eort an eort to solve this problem, Congress included a provision in the
FDAMA oering economic incentives to pharmaceutical companies to conduct testing on children in Section
111 of the Act.
The birth of the pediatric exclusivity provision occurred in 1990, when attendees of a workshop held at
the Institute of Medicine (\IOM")110 recommended market-based incentives as a proposal to increase pe-
diatric studies and labeling.111 They named the proposal the \Better Pharmaceuticals for Children Act
(\BPCA")."112 Following the IOM workshop, pharmaceutical industry representatives urged Senator Nancy
Kassebaum (R-Kan.) to introduce the BPCA to Congress.113 Congress passed and signed the BPCA into
107See Blumer supra note 40 at 596.
108Id.
109Id.
110The Institute of Medicine (``IOM'') is part of the National Academy of Sciences, a private,
non-governmental organization. The IOM seeks to advance and disseminate scientific knowledge to the
government, the private sector, the professions, and the public in an effort to improve human health.
111See Institute of Med., National Academy of Sciences, Drug Development and the Pediatric Population: Report
of a Workshop 12 (1991). (``Marion Finkel clarified the industry perspective of the FDA guidelines promoting
pediatric drug studies...Pharmaceutical industry resources will be required by the initiatives therefore,
incentives, such as exclusivity or some patent term extension, would be valuable.'')
112See id.
113See S. 3337, 102d Cong., 2d Sess. (1992) (proposing deferred effective dates for approval of applications
under drug provisions. The purpose of the BPCA was to encourage the innovator industry to conduct pediatric
testing on drug products not solely intended for use in children -- e.g. drugs prescribed on an off-label
basis for children -- in exchange for six months of market exclusivity.)
20law as part of the FDAMA in 1997.114
Although the Modernization Act does not mandate the inclusion of children in clinical trials, it does provide
substantial nancial incentives for manufacturers to undertake such studies. The primary incentive provided
in the law is extending market exclusivity by six months to any existing period of marketing exclusivity or
continuing patent protection if a drug sponsor agrees to conduct clinical trials in children.115 The pediatric
studies do not have to result in new labeling for the tested drugs, nor do the studies have to show safety and
ecacy in pediatric patients.116 Not only is the six months of additional patent protection for the specic
drug tested, but it also applies to the drug's active moiety,117 the part of the drug's make-up that causes its
physiological or pharmacological action.118 In certain limited circumstances, sponsors of such studies can
earn an additional six-month exclusivity period.119
At the time this provision was in enacted, it was predicted that the economic impact of the law would be
substantial. Estimates ranged up to $4 billion of additional sales revenue for brand manufacturers for the
rst 26 drugs tested subsequent to the new law.120 Merck, for instance, is estimated to have gained nearly
$300 million in sales for having tested Pepcid on infants, in accordance with FDAMA Section 111.121
114See FDCA 505A; 21 U.S.C. 355a (Supp. 1997) (providing market exclusivity for sponsors who conduct
pediatric studies of drugs). The inclusion of the BPCA in the FDAMA was a priority issue for Congress, second
only to the reauthorization of the PDUFA. See Pub. L. No. 105-115, 111 Stat. 2296 (codified at 21 U.S.C.
301-392 (Supp. 1997)) (intending, among other things, to improve the regulation of food, drugs, devices, and
biological products).
115See FDCA 505A(a), (c); 21 U.S.C. 355a(a), (c) (Supp. 1997) (extending market exclusivity for certain
sponsors who conduct pediatric drug studies).
116See Elizabeth H. Dickinson, FDA's Role in Making Exclusivity Determinations, 54 Food & Drug L.J. 195,
203 (1999) (indicating that the goal of the broad grant of exclusivity is to get a maximum amount of useful
pediatric information, and make this information public).
117See National Pharm. Alliance v. Henney, 47 F. Supp. 2d 37, 39-40 (D.D.C. 1999) (holding that the term
``drug'' in FDAMA Section 111 should be interpreted as active moiety). This court's interpretation of the
FDAMA Section 111 in Henney substantially increased the number of drugs to which market exclusivity could be
extended, thereby increasing the value of the incentive to drug manufacturers.
118See 21 C.F.R. 314.108(a) (1999) (defining ``active moiety'' as ``the molecule or ion, excluding
those appended portions of the molecule that cause a drug to be an ester, salt..., or other noncovalent
derivative..., responsible for the physiological or pharmacological action of the drug substance'')
119See FDCA 505A(h); 21 U.S.C. 355a(h) (Supp. 1997) (providing that drug sponsors may receive an additional
six-month period if they satisfy all of the other requirements of this section).
120Coopman supra note 31 at RX 8.
121See id.
21There are, however, exceptions as to which drugs qualify for market exclusivity under the Modernization
Act. For example, time must still remain on the patent, or the drug must not yet be approved.122 Further-
more, drug sponsors can earn market exclusivity only for products listed in the \Orange Book"123 which
are eligible for market exclusivity or protected under either the Drug Price Competition and Patent Term
Restoration Act124 or the Orphan Drug Act.125
The initiative to conduct pediatric studies does not lie solely with drug companies under the Modernization
Act. The Act outlines a multi-step procedure by which the FDA must rst determine which drugs should
be studied in children.126 Moreover, the FDA must then initiate agreements with drug manufacturers to
conduct such studies. After determining that information about a drug may produce health benets among
a pediatric population,127 the Secretary of the Department of Health and Human Services (\DHHS") must
request in writing for the drug sponsor to conduct pediatric studies.128 The written request addresses, among
other things, the type of studies to be performed, study design, appropriate age study groups, and clinically
endpoints to ensure that studies eligible for pediatric exclusivity provide meaningful safety and ecacy in-
formation on the use of the drug in relevant pediatric age groups.129 Even after receipt of a written request,
the drug sponsor is not obligated in any way to conduct pediatric studies and is allowed at its discretion to
122See generally FDAMA 111 (codified at FDCA 505A, 21 U.S.C. 355a (Supp. 1997)).
123See Food & Drug Admin., Approved Drug Products with Therapeutic Equivalence Evaluations (CCH 18th ed. 1998)
(listing the different types of drug patents that exist and the drugs that are currently protected under those
patent categories.)
124See Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified in scattered sections of 15 U.S.C., 28 U.S.C., 35
U.S.C., and 42 U.S.C.) (amending the FDCA to revise procedures for new drug applications, amending Title 35 of
the U.S.C., and authorizing the extension of patents for certain regulated products.) This Act is also known
commonly known as the Hatch-Waxman Act.
125See Pub. L. No. 97-414, 1-4, 96 Stat. 2049-56 (1983) (codified in scattered sections of 21 U.S.C., 26
U.S.C., and 42 U.S.C.). The FDCA identifies drugs for rare diseases or conditions. See FDCA, Pub. L. No.
75-717, 526(a) (2) (A)-(B), 52 Stat. 1040 (1938) (codified as amended at 21 U.S.C. 360bb(a) (2) (A) -- (B)
(1994)) (defining ``rare disease or condition'' as one which affects fewer than 200,000 people in the United
States for which drug sales are not reasonably expected to exceed drug development costs.
126See FDCA 505A(b); 21 U.S.C. 355a(a) (Supp. 1997) (outlining FDA procedures to determine which drugs should
be tested in children.)
127See FDCA 505A(b); 21 U.S.C. 355a(b) (Supp. 1997) (requiring the DHHS to develop list of drugs which may
produce healthy benefits in the pediatric population and, thus, qualify for exclusivity.)
128See FDCA 505A(d); 21 U.S.C. 355a(d) (Supp. 1997) (stipulating the various procedures and protocols
involved in applications for pediatric exclusivity).
129See id.
22conduct such studies only to reap the benets of the market exclusivity incentive.130 Finally, the Act directs
the FDA to annually update the listing of drugs for which additional pediatric information may improve
children's health.131 Since the FDAMA came into eect, the FDA has requested studies to be performed on
a signicant number of drugs, covering a variety health ailments prevalent in children132
Because Congress passed the Modernization Act after the FDA's proposed rule mandating pediatric study(but
before the rule was nalized), the necessity of both incentives has been questioned since their passing. Yet,
both the Final Rule and the pediatric exclusivity provision, as eorts to increase the number of children in
clinical trials that test the eects of drugs on them, are necessary when examined closely. First, the Final
Rule is intended to be product-specic. As such, the Final Rule is limited only to a specic indication for a
specic drug product, whereas the Modernization Act applies to the entire active moiety of a drug product.
The Final Rule shifts the inquiry from whether children should be tested to when children should be tested.
The pediatric exclusivity provision, on the other hand, provides an economic incentive for drug sponsors to
comply with the FDA's Final Rule. In achieving the goals of both initiatives, which is to have more clinical
trials that are inclusive of children conducted, the Modernization Act is still an incentive to do such, even if
the FDA's authority to mandate pediatric research is challenged. 133 Insofar as the Modernization Act and
the Final Rule may overlap, it is the FDA's responsibility to notify drug sponsors about the possibility of
gaining FDAMA market exclusivity.
130See CDER, FDA, Guidance for Industry: Qualifying for Pediatric Exclusivity under Section 505A of the
Federal Food, Drug and Cosmetic Act, at 4 (Sept. 1999) http://www.fda.gov/cderguidanceindex.htm (``Issuance
of a written request to a sponsor does not require the sponsor to conduct pediatric studies described in the
written request. It is the sponsor's decision whether to conduct the studies and possibly gain pediatric
exclusivity'').
131See FDCA 505A; 21 U.S.C. 355a(b) (Supp. 1997) (requiring the Secretary of the DHHS to consult with experts
in pediatric research to develop and publish a list of drugs that may qualify for pediatric exclusivity not
later than 180 days from the enactment of the FDAMA).
132The FDA has issued 137 Written Requests for pediatric studies under 505A of the Federal Food, Drug, and
Cosmetic Act (visited April 20, 2001) http://www.fda.gov/cder/pediatric/wrlist.htm.
133See discussion of the questionability of the FDA's authority to promulgate the Final Rule supra at Section
III.
23In compliance with the FDAMA's requirement for the FDA report to Congress on the eectiveness and
adequacy of pediatric exclusivity provision, the FDA released a report on the status of the section (\status
report"), including suggestions for modication, on January 1, 2001.134 Although initial reports showed
that the FDA was slow to grant the market exclusivity incentives promised in the Modernization Act,135
the status report concludes that the pediatric exclusivity provision has been highly eective in achieving
its goal of generating pediatric studies on many drugs and in providing useful new information in labeling
drugs and biological products. More specically, at the time the report was written, the FDA had issued
more than 157 written requests asking for 332 studies. These studies would potentially involve more than
20,000 pediatric patients. Additionally, the FDA reported that it had received more than 191 proposals from
sponsors to conduct pediatric studies. In fewer than three years, more than 58 pediatric studies had already
been conducted. Reports from these studies had been submitted, and exclusivity granted to 25 drugs. The
status report indicated that drugs that have or soon will have pediatric use information in their labeling
include those drugs used to treat conditions in children such as HIV, asthma, diabetes, acid reux disease,
hypertension, juvenile rheumatoid arthritis, obsessive-compulsive disorder, and pain.
In addition to reporting on the eectiveness of provision, the status report also addresses the adequacy and
the economic impact of the provision, while also making recommendations for modications of the provision
when it expires January 1, 2002. With regard to the provision's adequacy, the status report said that the
current exclusivity provision is inadequate as an incentive for drug sponsors to conduct testing on older
antibiotics and other drugs lacking market exclusivity or patent protection. Moreover, the incentive is not
adequate to encourage research trials for certain younger age groups, especially the neonatal age group for
134See FDCA 505A(k); 21 U.S.C. 355a(k) (Supp. 1997) (providing that the FDA shall conduct
a study and report to Congress not later than January 1, 2001). See the full report at
http://www.fda.gov/cder/pediatric/reportcong01.pdf., herein after cited as ``Status Report to Congress.''
135Karst supra note 68 at 767.
24whom an appropriate trial cannot be designed until studies of older pediatric age groups have been submitted
and analyzed.
The status report also found that the provision's market exclusivity incentive is also inadequate failure to
encourage studies in drugs with low sales because the value of the exclusivity does not oset the costs of the
studies. As a result, a number of drugs that have been identied as important to children, but for which
the incentive has little or no value, remain unstudied. For example, of the ten most frequently prescribed
drugs for children that lacked adequate labeling as set forth by the FDA in 1994, six have no remaining
exclusivity or patent life. As such, their sponsors were unable to take advantage of incentives under the
pediatric exclusivity program. Thus, even after the passage of the Modernization Act, the six drugs remain
inadequately studied and labeled for the pediatric population.
Finally, the status report showed that although a second period of exclusivity is available in the law, it, too,
is inadequate because its limited scope precludes sponsors from being able to utilize this option.
While the pediatric exclusivity provision should reduce certain types of health care expenditures, it also
increases others. The status report estimates that the cost of pediatric exclusivity will add less than one-
half of 1 percent to the nation's pharmaceutical bill. Yet, while it is predicted that better drug treatment
information will permit quicker recoveries from childhood illnesses, with fewer attendant hospital stays,
physician visits and parental workdays lost, the extended exclusivity will also delay the introduction of
lower-priced generic drugs into the market. Delaying the introduction of generic drugs from entering the
markets temporarily raises the average price of prescription drugs, thus, particularly aecting the elderly
and the uninsured population.
Although the report recommends renewal of the pediatric exclusivity provision after its sunset in 2002, it also
recommends modications to increase the program's eectiveness. The primary modication is for Congress
25to develop alternative incentives to address gaps in the current law regarding specic groups of children and
classes of drugs for which current exclusivity provisions are inadequate or do not apply. Moreover, the status
report acknowledges the great burden the provision places on the elderly and the uninsured because of the
delay in generic drugs on the market as a result of the extension of brand name patents under the provision.
As such, it encourages Congress to weigh costs of the provision and, if Congress determines that the costs of
the provision outweighs its benets, then the size of the incentive should be reduced.136 When viewed in its
totality, however, the report concludes that the pediatric exclusivity provision has been eective in achieving
its goal of providing dosing and safety information to physicians and to consumers by having information
regarding safety on product labels.137
VII.
RECOMMENDATIONS FOR MODIFICATION TO THE PEDIATRIC
EXCLUSIVITY PROVISION138
The purported successes of the Modernization Act in encouraging drug sponsors to conduct more clinical
trials including children with the opportunity for patent extension on the tested drug make it dicult to
question whether Congress should renew the provision beyond its scheduled sunset date of January 1, 2002.
There is more information regarding the eects of drugs on children available to clinicians for administering
drugs to children and more information for product labeling than ever before.
In considering whether to renew the pediatric exclusivity provision, as suggested by the status report,
Congress must seriously evaluate the costs of granting such an incentive and, more importantly, evaluate
136See Status Report to Congress at 18.
137See generally, Status Report to Congress, supra note 134.
26who is actually bearing the burden of these costs. It is estimated that over the next 20 years, the pediatric
exclusivity provision will cost consumers an additional 13.9 billion dollars. Over that time, according to the
FDA's projections, brand-name drug-makers will gain 29.6 billion dollars, the generic industry will lose 10.7
billion dollars, and drug distributors, including pharmacies will lose 4.9 billion dollars.139 Assuming this is
an accurate estimate, an evaluation of these numbers reveals that the overwhelming nancial burden of the
pediatric market exclusivity provision lies with the consumer. The extension of market exclusivity to name
brand drugs keeps the prices of prescription drugs higher due to the unavailability of generic drugs. More
than likely, the most aected sector of the population is the elderly and the poor. To counter the eects of
the provision's incentive on these populations, Congress should revise the Modernization Act and implement
a two-tiered incentive plan for drug sponsors that conduct clinical trials inclusive of the pediatric population.
A two-tiered incentive plan would not only lessen the burden on consumers, particularly the elderly and
the poor populations, but it would also combat the shortcomings of the Modernization Act including (1)
its failure to encourage testing about the eects of drug therapy on all sectors of the pediatric populations,
including neonates and infants; and (2) the absence of an incentive to conduct testing on drugs that do not
qualify for patent exclusivity extensions due to expired patents. Moreover, a two-tiered incentive plan will
further increase the amount of information available regarding the eects of commonly prescribed drugs on
the pediatric population, which is the ultimate goal of the provision.
Tier-one of the incentive plan would allow the pediatric exclusivity provision to remain similar to its present
state, with some modications. As the provision stands today, a drug that has been tested on children
139S. Stolberg, Children Test New Medicines Despite Doubts, N.Y. Times (February 11, 2001) at 1.
27for safety and ecacy may qualify for a six-month extension on its patent, provided that the patent has
not already expired. Congress should modify this and allow drugs to qualify for a nine-month extension
under the pediatric exclusivity provision if (1) the tested drug leads to a change in labeling for the pediatric
population; (2) the drug is the rst in its particular therapeutic class to be tested on children; or (3) the
drug has been tested on all cross-sections of the pediatric population, including neonates and infants.
Limiting the drugs that qualify for patent exclusivity achieves many of the goals the pediatric exclusivity
provision fails to meet in its present state. Most signicantly, such limitations will reduce the number of
drugs that receive the market exclusivity incentive, thus, lessening the burden on consumers. While these
requirements set the incentive qualifying bar for drug sponsors higher, the nancial gain drug sponsors receive
as a result of the new nine-month patent exclusivity would make it worth the extra eort. These limitations
essentially shift the nancial burden from consumers to drug sponsors, while simultaneously providing them
a highly valuable and attainable incentive.
In addition to shifting the burden of the incentive plan from consumers to drug sponsors, these limitations
will encourage faster and better pediatric studies, especially with the granting of market exclusivity to only
the rst drug of a particular therapeutic class. This provision is similar to the standard used in the orphan
drug context, where a subsequent sponsor seeking orphan status must show clinical superiority in order to
defeat a previous sponsor's orphan exclusivity for a particular drug and qualify for its own exclusivity. As
a result of this modication, there will be fewer unnecessary duplicative studies on drugs of the same class.
Furthermore, drug companies would not be able to maintain market exclusivity on an entire class of drugs
that essentially provide the same treatments, thus, rarely providing any new information on the eects of
these treatments on children.
28The nal provision under which a drug sponsor can get an extension on market exclusivity of a drug is by
testing the drug on all cross-sections of the pediatric population. While there has been a substantial increase
in the information available about the eects of certain drug therapies on certain pediatric populations as a
result of the incentives provided in the Modernization Act, information regarding the eects of drug thera-
pies on infants and neonates is still insucient. As such, this provision for patent exclusivity extension will
encourage drug sponsors to conduct clinical trials in this sector of the pediatric population as well.
Although limiting grants of patent exclusivity to those drugs that meet the previously outlined criteria,
Congress should also create a second-tier incentive to ensure that drug companies do not dismiss the Mod-
ernization Act incentive provision as unattainable, and forego all pediatric clinical trials. There should be
an alternative, second-tier incentive for drug sponsors to test drugs in pediatric populations that will not
qualify for the market exclusivity extension, such as those drugs with expired patents, drugs of a class that
have already received the extension under the rst-tier, and drugs for which it is too costly or unfeasible
to design a plan for testing on neonates and infants. This second-tier incentive would be to provide drug
companies with a one time tax benet to conduct such studies. This benet rewards drug companies without
burdening consumers and drug distributors through excessive grants of market exclusivity, which delay the
entrance of generic drugs and other lower price competitors into the market. Although this provision may
not be as appealing as the extension on market exclusivity as provided in the rst-tier, it will encourage
drug sponsors to conduct testing of their drugs on children, especially if the tax incentive is substantial.
Under this proposed scheme, the Modernization Act will continue to increase the amount of information
available to clinicians and for labels regarding the eects of drug therapies on children by oering drug
sponsors incentives to conduct such testing. Placing further limitations on drugs that qualify for patent
29exclusivity will alleviate the economic burden consumers, especially the most vulnerable of our population,
experience as a result of the delay of the introduction of lower drug competitors into the market. While
extension of market exclusivity from six- months to nine-months for qualifying drugs may have a counter
eect and further delay the entry of some generic drugs into the market, the strict limitations of this provision
will keep such to a minimum. Finally, the second-tier incentive, which will provide a one time tax benet for
drugs that have been tested on children but do not qualify under the rst-tier, will encourage drug sponsors
to conduct clinical trials in the pediatric population, especially testing drugs on children that already have
expired patents, without causing economic harm to consumers and drug distributors.
CONCLUSION
More than 60 to 70 percent of all drugs have no indication for their use in children under age 12. The
Final Rule and the pediatric exclusivity provision are the latest eorts to solve this problem of children as
\therapeutic orphans." Although the FDA Final Rule mandates drug sponsors to conduct clinical trials
that include children, the statutory authority of the FDA to enforce such a rule is questionable, and may
be challenged by the pharmaceutical industry in the future. As such, it is imperative that Congress renew
the pediatric exclusivity provision in the FDAMA so as to continue increasing the amount of information
available about the eects of drugs in children. In renewing this provision, Congress should adopt an incentive
plan that rewards drug manufacturers for conducting such clinical trials but not one that simultaneously
harms consumers. Thus, a two-tiered incentive plan which extends patent life to drug studies providing the
most comprehensive information about their eects in children and tax benets to other drug studies that
include children, is an alternative, and perhaps better plan, for the pediatric exclusivity provision of the
Modernization Act.
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